Group 1 - The stock price of BGM increased by 5.37% to $9.81 per share, with a total market capitalization of $1.805 billion as of July 31 [1] - For the fiscal year ending March 31, 2025, BGM reported total revenue of $14.3114 million, representing a year-over-year growth of 13.92%, while the net profit attributable to shareholders was a loss of $0.8612 million, a decrease of 307.79% compared to the previous year [1] - BGM, formerly known as Qilian International Holdings Group, is headquartered in Chengdu, China, and focuses on innovative solutions in the biopharmaceutical, biorefining, and healthcare sectors [1] Group 2 - The company's product range includes raw materials for oxytetracycline, licorice preparations, and crude heparin sodium, which are essential for both human pharmaceuticals and the global livestock industry [1] - Oxytetracycline raw materials are used to produce human antibiotics and support the safety of poultry and seafood in the livestock sector [1] - Crude heparin sodium is processed into refined heparin sodium and injectable heparin sodium solutions, serving as a major anticoagulant, while licorice preparations, such as compound licorice tablets, are used as cough remedies supplied to retail pharmacies [1]
博美集团上涨5.37%，报9.81美元/股，总市值18.05亿美元